1. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
- Author
-
Ismet Aydogdu, Zafer Gokgoz, Serdal Korkmaz, Mehmet Sinan Dal, Mehmet Yilmaz, Gulsum Akgun Cagliyan, Orhan Ayyildiz, Fevzi Altuntaş, Ali Kaya, Mehmet Şencan, Omur Gokmen Sevindik, Cengiz Demir, Bulent Eser, Yusuf Bilen, Alma Aslan, Aliihsan Gemici, Fahri Şahin, Mehmet Hilmi Dogu, Meltem Olga Akay, Hatice Terzi, [Gemici, Aliihsan] Sanliurfa Mehmet AkifInan Training & Res Hosp, Div Hematol, Sanliurfa, Turkey -- [Aydogdu, Ismet] Celal Bayar Univ, Dept Hematol, Manisa, Turkey -- [Terzi, Hatice -- Sencan, Mehmet] Cumhuriyet Univ, Dept Hematol, Sivas, Turkey -- [Aslan, Alma] Hacettepe Univ, Dept Med Oncol, Ankara, Turkey -- [Kaya, Ali Hakan -- Dal, Mehmet Sinan -- Altuntas, Fevzi] Ankara Oncol Training & Res Hosp, Hematol & Stem Cell Transplantat Clin, Ankara, Turkey -- [Akay, Meltem Olga] Osmangazi Univ, Dept Hematol, Eskisehir, Turkey -- [Dogu, Mehmet Hilmi] Istanbul Training & Res Hosp, Div Hematol, Istanbul, Turkey -- [Ayyildiz, Orhan] Dicle Univ, Dept Hematol, Diyarbakir, Turkey -- [Sahin, Fahri] Ege Univ, Dept Hematol, Izmir, Turkey -- [Cagliyan, Gulsum Akgun] Denizli State Hosp, Div Hematol, Denizli, Turkey -- [Yilmaz, Mehmet] Gaziantep Univ, Dept Hematol, Gaziantep, Turkey -- [Gokgoz, Zafer] Ordu State Hosp, Div Hematol Ordu, Ordu, Turkey -- [Bilen, Yusuf] Ataturk Univ, Dept Hematol, Erzurum, Turkey -- [Demir, Cengiz] Yuzuncu Yil Univ, Dept Hematol, Van, Turkey -- [Sevindik, Omur Gokmen] Firat Univ, Dept Hematol, Elazig, Turkey -- [Korkmaz, Serdal] Kayseri Training & Res Hosp, Div Hematol, Kayseri, Turkey -- [Eser, Bulent] Erciyes Univ, Dept Hematol, Kayseri, Turkey, Altuntas, Fevzi -- 0000-0001-6872-3780, Division of Hematology, Sanliurfa Mehmet AkifInan Training and Research Hospital, Sanliurfa, Turkey, Department of Hematology, Celal Bayar University, Manisa, Turkey, Department of Hematology, Cumhuriyet University, Sivas, Turkey, Department of Medical Oncology, Hacettepe University, Ankara, Turkey, Hematology and Stem Cell Transplantation Clinic, Ankara Oncology Training and Research Hospital, Ankara, Turkey, Department of Hematology, Osmangazi University, Eskisehir, Turkey, Division of Hematology, Istanbul Training and Research Hospital, Istanbul, Turkey, Department of Hematology, Dicle University, Diyarbakir, Turkey, Department of Hematology, Ege University, Izmir, Turkey, Division of Hematology, Denizli State Hospital, Denizli, Turkey, Department of Hematology, Gaziantep University, Gaziantep, Turkey, Ordu State Hospital, Division of Hematology, Ordu, Turkey, Department of Hematology, Ataturk University, Erzurum, Turkey, Department of Hematology, YuzuncuYil University, Van, Turkey, Department of Hematology, Firat University, Elazig, Turkey, Division of Hematology, Kayseri Training and Research Hospital, Kayseri, Turkey, and Department of Hematology, Erciyes University, Kayseri, Turkey
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,overall survival ,Salvage therapy ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Chemoimmunotherapy ,Median follow-up ,DHAP ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Aged ,Retrospective Studies ,treatment ,business.industry ,nodular lymphocyte predominant Hodgkin's lymphoma ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Nodular lymphocyte predominant Hodgkin's lymphoma ,Lymphoma ,Surgery ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,progression-free survival ,Progressive disease ,030215 immunology - Abstract
WOS: 000425633300017, PubMed ID: 28707314, Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.
- Published
- 2017